RxDoctor Payments Data

Conrad Knudson, MD

Family Medicine · York, PANPI 1699773481

Payments from drug & device makers

$1,045in general payments, 2019–2025

Across 62 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$454
  • Supernus Pharmaceuticals, Inc.$95
  • Pfizer$88
  • E.r. Squibb & Sons, L.L.C.$78
  • Novo Nordisk$71
  • Lilly USA, LLC$37
  • plus $222 from 12 others

What the payments were for

  • Food & beverage$1,03499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,045 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$128,968
Medicare patients
374
Services billed
1,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban264$262,314
OzempicSemaglutide70$94,586
JardianceEmpagliflozin68$74,458
RybelsusSemaglutide41$62,857
XareltoRivaroxaban54$60,371
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$56,994
TrulicityDulaglutide25$32,514
MounjaroTirzepatide19$25,537
Breo ElliptaFluticasone/Vilanterol53$25,458
JanuviaSitagliptin Phosphate15$22,602
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$19,177
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$12,337
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$11,529
Atorvastatin Calcium1,154$10,559
Gabapentin297$9,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$262,314264 claims
Novo NordiskOzempic, Rybelsus$71$157,443111 claims
Johnson & JohnsonXarelto$16$60,37154 claims
Lilly USA, LLCTrulicity, Mounjaro$37$58,05144 claims
MerckJanuvia$13$22,60215 claims
AstraZenecaBrilinta, Nexium$12$8,93025 claims
AbbVieSynthroid$454$4,34866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →